PMID- 16908592
OWN - NLM
STAT- MEDLINE
DCOM- 20061012
LR  - 20171116
IS  - 1541-7786 (Print)
IS  - 1541-7786 (Linking)
VI  - 4
IP  - 8
DP  - 2006 Aug
TI  - Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian 
      cancer cells.
PG  - 511-20
AB  - Chronic inflammation is implicated in the pathophysiology of ovarian cancer. 
      Tumor necrosis factor-alpha (TNF-alpha), a major inflammatory cytokine, is 
      abundant in the ovarian cancer microenvironment. TNF-alpha modulates the 
      expression of CD44 in normal T lymphocytes and CD44 is implicated in ovarian 
      carcinogenesis and metastases. However, little is known about the role of 
      TNF-alpha in CD44 expression of cancer cells. Recent clinical work using 
      TNF-alpha inhibitors for the treatment of ovarian cancer makes the study of 
      TNF-alpha interactions with CD44 crucial to determining treatment a success or a 
      failure. We studied the effect of TNF-alpha on ovarian cancer cells viability, 
      CD44 expression, and in vitro migration/invasion. Our results revealed that 
      TNF-alpha differentially modulates the expression of CD44 in TNF-alpha-resistant 
      ovarian cancer cells, affecting their in vitro migration, invasion, and binding 
      to hyaluronic acid. TNF-alpha up-regulation of CD44 expression was dependent on 
      the activation of c-Jun NH(2)-terminal kinase (JNK) and this activation was 
      accompanied by an increase in their invasive phenotype. On the contrary, if 
      TNF-alpha failed to induce JNK phosphorylation, the end result was 
      down-regulation of both CD44 expression and the invasive phenotype. These results 
      were confirmed by the use of JNK inhibitors and a TNF receptor competitive 
      inhibitor.
FAU - Muthukumaran, Neelakandan
AU  - Muthukumaran N
AD  - Division of Gynecologic Oncology, The Cancer Institute of New Jersey, University 
      of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Room 
      2009, 195 Little Albany Street, New Brunswick, 08901, USA.
FAU - Miletti-Gonzalez, Karl E
AU  - Miletti-Gonzalez KE
FAU - Ravindranath, Abhilash K
AU  - Ravindranath AK
FAU - Rodriguez-Rodriguez, Lorna
AU  - Rodriguez-Rodriguez L
LA  - eng
GR  - CA66077/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Cancer Res
JT  - Molecular cancer research : MCR
JID - 101150042
RN  - 0 (CD44 protein, human)
RN  - 0 (Drug Combinations)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Laminin)
RN  - 0 (Proteoglycans)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 119978-18-6 (matrigel)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 9007-34-5 (Collagen)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Collagen/drug effects
MH  - Drug Combinations
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - Hyaluronic Acid/metabolism
MH  - Laminin/drug effects
MH  - Neoplasm Invasiveness
MH  - Ovarian Neoplasms/*metabolism
MH  - Proteoglycans/drug effects
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/metabolism/*pharmacology
EDAT- 2006/08/16 09:00
MHDA- 2006/10/13 09:00
CRDT- 2006/08/16 09:00
PHST- 2006/08/16 09:00 [pubmed]
PHST- 2006/10/13 09:00 [medline]
PHST- 2006/08/16 09:00 [entrez]
AID - 4/8/511 [pii]
AID - 10.1158/1541-7786.MCR-05-0232 [doi]
PST - ppublish
SO  - Mol Cancer Res. 2006 Aug;4(8):511-20. doi: 10.1158/1541-7786.MCR-05-0232.